Option

Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes

Monday, July 6, 2020 - 9:02pm

Pacira also intends to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45.0 million aggregate principal amount of notes.

Key Points: 
  • Pacira also intends to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45.0 million aggregate principal amount of notes.
  • The terms of the notes, including the interest rate, initial conversion rate and other terms, will be determined by negotiations between Pacira and the initial purchasers of the notes.
  • These activities may affect the trading price of Pacira common stock and, if conducted concurrently with this offering, may result in a higher initial conversion price for the notes Pacira is offering.
  • There can be no assurance that we will be able to complete the proposed offering on the anticipated terms, or at all.

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Monday, July 6, 2020 - 5:58pm

All of the ADSs are being offered by Ascendis.

Key Points: 
  • All of the ADSs are being offered by Ascendis.
  • In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of ADSs at the public offering price, less the underwriting commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thursday, July 2, 2020 - 12:00pm

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • For more information, please visit the Company's website at www.BioCryst.com .

Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, July 1, 2020 - 9:48pm

The stock option was granted as an inducement material to Mr. Musils entering into employment with Catalyst in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted as an inducement material to Mr. Musils entering into employment with Catalyst in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Notwithstanding the foregoing, the stock option will accelerate upon certain terminations of employment, including within a certain period following a change in control transaction.
  • Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders.
  • The Company does not assume any obligation to update any forward-looking statements, except as required by law.

OCC June 2020 Total Volume Up Nearly 81 Percent from a Year Ago

Wednesday, July 1, 2020 - 9:30pm

OCC, the worlds largest equity derivatives clearing organization, announced today that June 2020 total cleared contract volume was 693,042,180 contracts, the U.S. equity options industrys highest month ever up 80.7 percent from June 2019 volume and beating the previous record of 670,646,998 cleared contracts set in March 2020 by 3.34 percent.

Key Points: 
  • OCC, the worlds largest equity derivatives clearing organization, announced today that June 2020 total cleared contract volume was 693,042,180 contracts, the U.S. equity options industrys highest month ever up 80.7 percent from June 2019 volume and beating the previous record of 670,646,998 cleared contracts set in March 2020 by 3.34 percent.
  • View the full release here: https://www.businesswire.com/news/home/20200701005934/en/
    Options: Total exchange-listed options cleared contract volume was 688,544,510, up 82.2 percent from 377,890,573 contracts in June 2019.
  • This includes ETF option cleared contract volume of 245,472,882, a 69.7 percent increase compared to June 2019.
  • Securities Lending: The average daily loan value at OCC in June 2020 was $76,216,532,318.42, an 8.19 percent decrease compared to June 2019.

Urban Exposure plc: TR1 - Standard form for notification of major holdings

Wednesday, July 1, 2020 - 4:05pm

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points: 
  • ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h).
  • xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

Denny’s Corporation Announces Pricing of Offering of 8,000,000 Shares of Common Stock

Wednesday, July 1, 2020 - 2:03pm

SPARTANBURG, S.C., July 01, 2020 (GLOBE NEWSWIRE) -- Dennys Corporation (NASDAQ: DENN) (Dennys or the Company), franchisor and operator of one of Americas largest franchised full-service restaurant chains, today announced that it has priced its underwritten public offering of 8,000,000 shares of its common stock, $0.01 par value (Common Stock), at a public offering price of $9.15 per share of Common Stock.

Key Points: 
  • SPARTANBURG, S.C., July 01, 2020 (GLOBE NEWSWIRE) -- Dennys Corporation (NASDAQ: DENN) (Dennys or the Company), franchisor and operator of one of Americas largest franchised full-service restaurant chains, today announced that it has priced its underwritten public offering of 8,000,000 shares of its common stock, $0.01 par value (Common Stock), at a public offering price of $9.15 per share of Common Stock.
  • In addition, Dennys granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock.
  • Dennys expects to receive net proceeds of approximately $69.6 million (or approximately $80.1 million if the underwriters exercise in full their option to purchase additional shares of Common Stock) in the offering, after deducting the underwriters discounts and commissions and estimated offering expenses.
  • Dennys intends to use the net proceeds from the offering, including any net proceeds from the underwriters exercise of their option to purchase additional shares of Common Stock, for general corporate purposes.

Cboe Global Markets Completes EuroCCP Acquisition, Plans to Launch Cboe Europe Derivatives in First Half of 2021

Wednesday, July 1, 2020 - 9:26am

The acquisition paves the way for the planned launch of Cboe Europe Derivatives, a new Amsterdam-based futures and options market, in the first half of 2021, subject to regulatory approvals.

Key Points: 
  • The acquisition paves the way for the planned launch of Cboe Europe Derivatives, a new Amsterdam-based futures and options market, in the first half of 2021, subject to regulatory approvals.
  • Cboe plans to launch Cboe Europe Derivatives in the first half of 2021, subject to regulatory approvals.
  • Cboe Global Markets (Cboe: CBOE) is one of the world's largest exchange holding companies, offering cutting-edge trading and investment solutions to investors around the world.
  • Cboe Europe Limited and Cboe Europe B.V. are wholly-owned subsidiaries of Cboe Global Markets, Inc..

Cboe Global Markets Completes EuroCCP Acquisition, Plans to Launch Cboe Europe Derivatives in First Half of 2021

Wednesday, July 1, 2020 - 9:15am

The acquisition paves the way for the planned launch of Cboe Europe Derivatives, a new Amsterdam-based futures and options market, in the first half of 2021, subject to regulatory approvals.

Key Points: 
  • The acquisition paves the way for the planned launch of Cboe Europe Derivatives, a new Amsterdam-based futures and options market, in the first half of 2021, subject to regulatory approvals.
  • Cboe plans to launch Cboe Europe Derivatives in the first half of 2021, subject to regulatory approvals.
  • Cboe Global Markets (Cboe: CBOE) is one of the world's largest exchange holding companies, offering cutting-edge trading and investment solutions to investors around the world.
  • Cboe Europe Limited and Cboe Europe B.V. are wholly-owned subsidiaries of Cboe Global Markets, Inc..

Local dealership offers a multitude of flexible financing and online pre-approval options

Wednesday, July 1, 2020 - 2:00am

To counter this, the dealership's financing department implements a variety of strategies to help every applicant get approved for financing.

Key Points: 
  • To counter this, the dealership's financing department implements a variety of strategies to help every applicant get approved for financing.
  • To get started on the process, prospective shoppers can complete the dealership's secure online credit application .
  • For those that find going the traditional route for purchasing a vehicle is not an option, Continental Mitsubishi offers secondary financing .
  • Those interested in the flexible financing options described above are encouraged to make a digital journey to the Continental Mitsubishi website at http://www.continentalmitsubishi.com .